Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00929474 · ClinicalTrials.gov registry record · NA
BOOST - Benefit of Frequent Optimization After Cardiac Resynchronization Therapy Device Replacement
A NA study, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT00929474 is a NA study that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 17 participants.
The verdict
NCT00929474, a NA study, was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
Cardiac resynchronization therapy (CRT) has shown improvement in mortality and morbidity in patients with left ventricular systolic dysfunction and congestive heart failure. Additionally in CRT patients it has been demonstrated that optimizing paced/sensed atrioventricular (AV) and interventricular (V-V) timings leads to immediate hemodynamic benefits and further improves cardiac function. Recent studies have shown that optimal paced/sensed AV and V-V delays change over time, which raises the question of how often optimization should be repeated. Thus, frequent re-optimization of these delays might be beneficial for maintaining significant improvement of cardiac function. However, it remains to be evaluated whether timing optimization may be beneficial on patients who have received CRT for a number of years and are now having the CRT device replaced.
Interventions
- DEVICE QuickOpt - SJM CRT (Group 1)
- DEVICE Control - SJM CRT (Group 2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00929474
The ClinicalTrials.gov registry entry for NCT00929474 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QuickOpt - SJM CRT (Group 1) is the first listed.
NCT00929474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00929474 about?
NCT00929474 is a clinical study titled "BOOST - Benefit of Frequent Optimization After Cardiac Resynchronization Therapy Device Replacement". Cardiac resynchronization therapy (CRT) has shown improvement in mortality and morbidity in patients with left ventricular systolic dysfunction and congestive heart failure. Additionally in CRT patients it has been demonstrated that optimizing paced/sensed atrioventricular (AV) and interventricular ...
What is the current status of trial NCT00929474?
This trial is currently terminated. It is a NA study. The enrollment target is 17 participants. The study started on 2009-06. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00929474?
The interventions under investigation include: QuickOpt - SJM CRT (Group 1) (DEVICE), Control - SJM CRT (Group 2) (DEVICE).
Who is sponsoring clinical trial NCT00929474?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.